ADJUVANT CHEMOTHERAPY RESPONSE ON STAGE IB3, IIA2, AND IIB CERVICAL CANCER PATIENT AT PROF. DR. I.G.N.G NGOERAH GENERAL HOSPITAL IN 2021-2022

Abstrak

Cervical cancer has become attention and health problem due to increased number of case and death. There are various type of cervical cancer treatments. In Prof. Dr. I.G.N.G. Ngoerah General Hospital, neoadjuvant chemotherapy is used to reduce tumor size before surgery is performed on IB3, IIA2, IIB stage cervical cancer due to limited radiotherapy device. This study aims to investigate neoadjuvant chemotherapy response on IB3, IIA2, IIB stage cervical cancer. Data of patient characteristic and chemotherapy response were collected from patient medical record. The data was processed using univariate analysis. The IB3 stage has highest successful response proportion (70%), followed by IIA2 stage (64,3%), then IIB (54%).  Elderly patients (> 50 years old) have worse response compared to young patients (< 50 years old). Based on age, the highest percentage of complete chemotherapy responses was in the age range of 40-49 years (17%). Based on the parity group, the lowest parity group had the highest complete chemotherapy response (14%). There were 41% of patients with a poor response in the SCC group and 43% of patients with a poor response in the non-SCC group. When viewed from the degree of differentiation, the group with a good degree of differentiation has the highest percentage of complete responses (29%).  The group with the largest tumor size which is above 7 cm had the highest percentage of poor chemotherapy response (67%).